Literature DB >> 8820078

Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group.

S A Yousem1, G J Berry, P T Cagle, D Chamberlain, A N Husain, R H Hruban, A Marchevsky, N P Ohori, J Ritter, S Stewart, H D Tazelaar.   

Abstract

In 1990, an international grading scheme for the grading of pulmonary allograft rejection was instituted. The use of this classification has resulted in a uniformity of grading which has allowed inter-institutional collaborations and communication unique in allograft monitoring. In 1995 an expanded group of international pathologists convened and revised the original proposal. This article summarizes the updated classification for pulmonary allograft rejection. In brief, acute rejection is based on perivascular and interstitial mononuclear infiltrates. Each grade of acute rejection should mention the presence of coexistent airway inflammation, the intensity of which may also be graded. Chronic rejection is divided into bronchiolitis obliterans--active or inactive--and vascular atherosclerosis--accelerated arterial or venous sclerosis.

Entities:  

Mesh:

Year:  1996        PMID: 8820078

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  140 in total

Review 1.  The pulmonary physician in critical care 1: pulmonary investigations for acute respiratory failure.

Authors:  J Dakin; M Griffiths
Journal:  Thorax       Date:  2002-01       Impact factor: 9.139

2.  Pediatric heart and lung transplantation.

Authors:  Subash C Reddy; Steven A Webber
Journal:  Indian J Pediatr       Date:  2003-09       Impact factor: 1.967

3.  Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients.

Authors:  C Ashley Finlen Copeland; Laurie D Snyder; David W Zaas; W Jackson Turbyfill; W Austin Davis; Scott M Palmer
Journal:  Am J Respir Crit Care Med       Date:  2010-05-27       Impact factor: 21.405

Review 4.  Gastroesophageal reflux and altered motility in lung transplant rejection.

Authors:  J M Castor; R K Wood; A J Muir; S M Palmer; R A Shimpi
Journal:  Neurogastroenterol Motil       Date:  2010-05-26       Impact factor: 3.598

5.  The Role of TGF-β in the Association Between Primary Graft Dysfunction and Bronchiolitis Obliterans Syndrome.

Authors:  A DerHovanessian; S S Weigt; V Palchevskiy; M Y Shino; D M Sayah; A L Gregson; P W Noble; S M Palmer; M C Fishbein; B M Kubak; A Ardehali; D J Ross; R Saggar; J P Lynch; R M Elashoff; J A Belperio
Journal:  Am J Transplant       Date:  2015-10-13       Impact factor: 8.086

6.  Impact of forced vital capacity loss on survival after the onset of chronic lung allograft dysfunction.

Authors:  Jamie L Todd; Rahil Jain; Elizabeth N Pavlisko; C Ashley Finlen Copeland; John M Reynolds; Laurie D Snyder; Scott M Palmer
Journal:  Am J Respir Crit Care Med       Date:  2014-01-15       Impact factor: 21.405

Review 7.  Inflammation in lung transplantation for CF. Immunosuppression and modulation of inflammation.

Authors:  George B Mallory
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

8.  Cross sectional study of exhaled nitric oxide levels following lung transplantation.

Authors:  A J Fisher; E Gabbay; T Small; S Doig; J H Dark; P A Corris
Journal:  Thorax       Date:  1998-06       Impact factor: 9.139

9.  Transcript signatures of lymphocytic bronchitis in lung allograft biopsy specimens.

Authors:  Xiang Xu; Jeffrey A Golden; Gregory Dolganov; Kirk D Jones; Samantha Donnelly; Timothy Weaver; George H Caughey
Journal:  J Heart Lung Transplant       Date:  2005-08       Impact factor: 10.247

10.  Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy.

Authors:  Kenneth R McCurry; Aldo Iacono; Adrianna Zeevi; Samuel Yousem; Alin Girnita; Shahid Husain; Diana Zaldonis; Bruce Johnson; Brack G Hattler; Thomas E Starzl
Journal:  J Thorac Cardiovasc Surg       Date:  2005-08       Impact factor: 5.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.